Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) announced on August 21, 2026 that it has closed initial transactions marking its entry into the New York cannabis market through the planned acquisition of PharmaCann Inc.'s New York licence and assets. The company has formed Grown Rogue New York, LLC ("GRNY") as a 51/49 joint venture with a capital partner, supported by project-based financing commitments of up to $15 million. The transactions are structured to preserve ongoing operations and avoid a prolonged shutdown of PharmaCann's New York vertical platform ahead of a full acquisition.

Key Points

  • Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) is a flower-forward cannabis company based in Medford, Oregon
  • Grown Rogue has closed initial agreements — including exclusivity, consulting, lease, and funding arrangements — to begin transitioning PharmaCann's New York cannabis licence and assets
  • A capital partner invested $10 million for a 49% preferred equity interest in GRNY; an additional $5 million drawable term loan is committed, with total estimated project costs of approximately $12 million
  • Investors will be watching for execution of definitive purchase agreements, expected within four weeks, and subsequent regulatory approval of the change of control

GRNY Joint Venture Structure and $15 Million Capital Commitment

Grown Rogue New York, LLC was established as a 51/49 joint venture between Grown Rogue and a capital partner. The capital partner contributed $10 million for a 49% preferred equity interest, with Grown Rogue retaining 51%. The preferred equity is convertible into Grown Rogue subordinate voting shares at escalating prices starting at $0.55, with the company noting that conversion today would represent approximately 18.2 million shares and roughly 7% dilution. The same capital partner committed an additional $5 million through a drawable term loan. Grown Rogue estimates total project costs, including the acquisition, capital expenditures, and working capital, at approximately $12 million.

PharmaCann New York's Dispensaries and Hamptonburgh Production Facility

The planned acquisition includes PharmaCann's Hamptonburgh cultivation and manufacturing facility, featuring approximately 24,000 square feet of indoor flower canopy, 16,000 square feet of light-deprivation greenhouse canopy, and ethanol and hydrocarbon extraction infrastructure. Four Verilife® branded dispensaries are also included — two combination adult-use and medical locations and two medical-only sites. Before substantially slowing production in early 2026, the Hamptonburgh facility averaged more than 2,000 lbs of flower per month. The four dispensaries have averaged aggregate monthly sales of $1.7–$2.0 million over the past eighteen months.

Interim Operating Arrangements and Anticipated Acquisition Timeline

Under a Goods and Services Agreement, GRNY is managing PharmaCann New York's day-to-day operations during the interim period, including all four dispensaries. A secured loan of up to $9 million from GRNY to PharmaCann New York will fund the Hamptonburgh production ramp and working capital needs. The anticipated purchase price is approximately $4.5 million, with $3 million payable upon regulatory approval of the change of control. Grown Rogue anticipates a six-to-nine month production ramp at Hamptonburgh and projects New York operations will reach after-tax operating cash flow positivity within nine months, subject to execution of definitive agreements and regulatory approvals.

Cost Reduction Targets and Expected Financial Impact on Grown Rogue

Grown Rogue's CFO stated in the release that the company anticipates reducing annual costs by approximately $20 million through identified savings expected to be implemented over the first six months of oversight. The company projects after-tax monthly cash flow from operations of approximately $600,000 within 18 months, based on its current operating plan. These expectations are forward-looking and subject to material assumptions, including lease adjustments that account for more than 75% of anticipated savings and the assumption that Section 280E will no longer apply to operations by 2027. Mindset Capital, Grown Rogue's largest shareholder, introduced the company to the capital partner and is serving as a strategic adviser.